Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Assets (2016 - 2025)

Viking Therapeutics' Assets history spans 12 years, with the latest figure at $715.7 million for Q4 2025.

  • For Q4 2025, Assets fell 21.2% year-over-year to $715.7 million; the TTM value through Dec 2025 reached $715.7 million, down 21.2%, while the annual FY2025 figure was $715.7 million, 21.2% down from the prior year.
  • Assets for Q4 2025 was $715.7 million at Viking Therapeutics, down from $739.4 million in the prior quarter.
  • Across five years, Assets topped out at $967.5 million in Q1 2024 and bottomed at $150.9 million in Q1 2023.
  • The 5-year median for Assets is $375.6 million (2023), against an average of $492.4 million.
  • The largest annual shift saw Assets fell 25.75% in 2022 before it skyrocketed 541.19% in 2024.
  • A 5-year view of Assets shows it stood at $210.7 million in 2021, then fell by 20.0% to $168.5 million in 2022, then surged by 118.65% to $368.5 million in 2023, then skyrocketed by 146.5% to $908.3 million in 2024, then decreased by 21.2% to $715.7 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Assets are $715.7 million (Q4 2025), $739.4 million (Q3 2025), and $827.9 million (Q2 2025).